The P/B of 4.96 is above the peer median of ~4.6, and the forward P/E of 21.4 suggests investors expect continued earnings growth. This premium appears justified by PJT's revenue mix, which includes a restructuring business that historically performs well during credit stress, providing a hedge against M&A cyclicality. However, the PEG of 3.01 indicates that the market may be pricing in aggressive long-term growth, which could be vulnerable if the restructuring pipeline normalizes.

PJT's ROE is inherently volatile due to success-fee timing, but the trend shows improvement from 2024 lows. The DuPont decomposition reveals that the firm's profitability is driven by high asset utilization (ROA of 2.8% in Q2 2026) and a lean balance sheet, rather than leverage. With equity/assets at 0.56, PJT does not rely on debt to boost returns, which is a positive quality indicator. The efficiency ratio of 78.1% in Q2 2026, while high, reflects the compensation-heavy cost structure typical of advisory firms, and the sequential improvement suggests operating leverage is being captured.

The efficiency ratio is not directly comparable to banks with net interest income, but the trend indicates that revenue growth is outpacing expense growth. The Q4 2025 efficiency ratio of 9.8% is an anomaly likely due to a one-time revenue spike, while the more recent 78.1% is more representative. PJT's cost structure is dominated by compensation, which is variable and tied to deal closings, so the efficiency ratio can fluctuate widely. The improvement in Q2 2026 suggests that the firm is managing costs effectively despite aggressive hiring, which is a positive sign for margin sustainability.

PJT's capital adequacy is not measured by regulatory ratios like CET1, but the equity/assets ratio of 0.56 is robust for an advisory firm, reflecting a conservative balance sheet with no debt. Tangible book value per share has grown from $22.85 in Q1 2024 to $27.48 in Q2 2026, a compound annual growth rate of about 10%, driven by retained earnings. This capital strength provides flexibility for talent acquisition and share repurchases, though the firm's dividend yield of 0.5% is minimal, indicating that capital is primarily reinvested in the business.

The absence of a loan book means traditional asset quality metrics like NPL ratios are not applicable. However, the provision volatility in the income statement is a key item to monitor. The Q4 2025 spike appears tied to contingent liabilities from advisory engagements, possibly related to litigation or deal guarantees, and the subsequent normalization indicates these were not systemic credit issues. Investors should focus on the firm's receivables and the collectability of success fees, which are tied to deal closings and can be subject to delays or disputes.

Compared to peers, PJT trades at a premium on P/E (26.2x vs. Evercore's 20.4x and Moelis's 23.2x), but its P/B is in line with Evercore and below Moelis's 7.95. This suggests the market values PJT's earnings stability and growth prospects more highly, likely due to the counter-cyclical restructuring business. However, PJT's ROE of 4.8% is significantly lower than Evercore's 45.8% and Moelis's 35.6%, which may be a concern. The lower ROE is partly due to PJT's higher equity base and lower leverage, but it also reflects the lumpy revenue recognition. The premium valuation implies that investors expect PJT to close the ROE gap as revenue scales.